Document is current
Any future updates will be listed below
-
Authors
Alig, Stefan K. http://orcid.org/0000-0001-6825-702X
Shahrokh Esfahani, Mohammad
Garofalo, Andrea
Li, Michael Yu
Rossi, Cédric
Flerlage, Tim
Flerlage, Jamie E.
Adams, Ragini
Binkley, Michael S.
Shukla, Navika
Jin, Michael C.
Olsen, Mari
Telenius, Adèle
Mutter, Jurik A.
Schroers-Martin, Joseph G. http://orcid.org/0000-0003-4128-2537
Sworder, Brian J.
Rai, Shinya
King, Daniel A. http://orcid.org/0000-0001-6451-712X
Schultz, Andre
Bögeholz, Jan http://orcid.org/0000-0002-7196-1621
Su, Shengqin http://orcid.org/0000-0002-6946-8256
Kathuria, Karan R.
Liu, Chih Long http://orcid.org/0000-0002-6577-5427
Kang, Xiaoman
Strohband, Maya J.
Langfitt, Deanna http://orcid.org/0000-0003-0941-5360
Pobre-Piza, Kristine Faye
Surman, Sherri
Tian, Feng http://orcid.org/0000-0002-2657-5158
Spina, Valeria
Tousseyn, Thomas http://orcid.org/0000-0002-0397-1086
Buedts, Lieselot
Hoppe, Richard http://orcid.org/0000-0003-0125-0194
Natkunam, Yasodha http://orcid.org/0000-0002-9816-1018
Fornecker, Luc-Matthieu
Castellino, Sharon M.
Advani, Ranjana
Rossi, Davide
Lynch, Ryan
Ghesquières, Hervé
Casasnovas, Olivier
Kurtz, David M. http://orcid.org/0000-0002-6382-4651
Marks, Lianna J.
Link, Michael P.
André, Marc
Vandenberghe, Peter http://orcid.org/0000-0003-4719-1935
Steidl, Christian http://orcid.org/0000-0001-9842-9750
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Alizadeh, Ash A. http://orcid.org/0000-0002-5153-5625
- License Information
-
More Information
Article History
Received: 19 December 2022
Accepted: 28 November 2023
First Online: 11 December 2023
Competing interests
: S.K.A. reports speaker honoraria from Takeda. M.S.E. reports consultancy for Foresight Diagnostics. J.E.F. reports research funding from Seattle Genetics. B.J.S. reports consultancy for Foresight Diagnostics. A.S. is currently employed by Foresight Diagnostics. Y.N. reports consultancy for Roche & Leica Biosystems and research funding from Kite Pharma. D.R. reports consultancy, honoraria, research funding and travel support from AstraZeneca, Janssen, AbbVie, Gilead, MSD, BMS and BeiGene. R.L. reports research funding from TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen and Rapt, as well as consultancy for Cancer Study Group, SeaGen, Foresight Diagnostics and AbbVie. D.M.K. reports consultancy for Roche, Adaptive Biotechnologies and Genentech, equity ownership interest in Foresight Diagnostics, and patent filings, including patent issued, licensed and with royalties paid from Foresight. M.A. reports consultancy for Takeda, BMS, Karyopharm, Gilead and Incyte, research funding from Roche, Johnson & Johnson and Takeda, as well as travel support from Roche, BMS, Celgene, Gilead, AbbVie, AstraZeneca and Takeda. C.S. has performed consultancy for Bayer, and has received research funding from Epizyme and Trillium Therapeutics. M.D. reports research funding from AstraZeneca, Genentech, Varian Medical Systems and Illumina, ownership interest in CiberMed and Foresight Diagnostics, consultancy from AstraZeneca, Boehringer Ingelheim, BMS, Genentech, Gritstone Oncology, Illumina, Regeneron and Roche, and multiple issued and pending patents including patents licensed to Foresight Diagnostics and Roche. A.A.A. reports consultancy for Celgene, Chugai, Genentech, Gilead, Janssen, Pharmacyclics and Roche, scientific advisory board membership in the Lymphoma Research Foundation, and Professional Affiliations with the American Society of Hematology, American Society of Clinical Oncology, American Society of Clinical Investigation, Leukemia & Lymphoma Society, Research Funding from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the US National Institutes of Health, Celgene, BMS and Pfizer, patent filings including patent issued, licensed and with royalties paid from FortySeven, a patent pending and Licensed to Foresight, a patent pending relating to MARIA, a patent issued and licensed to CiberMed, a patent issued and a patent pending to CiberMed, patents issued to Idiotype Vaccines, and a patent issued, licensed and with royalties paid from Roche, and equity ownership interests in CiberMed Inc., ForeSight Diagnostics, FortySeven Inc. and CARGO Therapeutics. S.K.A., M.S.E., M.Y.L., B.J.S., D.M.K., C.S., M.D. and A.A.A. also report patent filings related to cancer biomarkers. The remaining authors declare no competing interests.
